Market Place
Sourcing Support
Insud Pharma completes acquisition of Agile Therapeutics
27 Aug 2024 //
EXPRESSPHARMA
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma
26 Jun 2024 //
GLOBENEWSWIRE
Agile Therapeutics Reports Q1 2024 Results, Corporate Update
15 May 2024 //
GLOBENEWSWIRE
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Agile Therapeutics Announces Delisting from Nasdaq
25 Mar 2024 //
GLOBENEWSWIRE
Correction - Agile to Report Fourth Quarter and Full Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Agile Therapeutics to Report 4Q and Full Year 2023 Financial Results
20 Mar 2024 //
GLOBENEWSWIRE
Agile Therapeutics Completes Pay-off of Debt
13 Mar 2024 //
GLOBENEWSWIRE
Agile Announces Exercise of Warrants for $4.8 Million Gross Proceeds
22 Feb 2024 //
GLOBENEWSWIRE
Agile Announces Extension Granted to Regain Compliance
15 Feb 2024 //
GLOBENEWSWIRE
Agile Provides Update on Actions to Strengthen Contraceptive Coverage Requirement
12 Dec 2023 //
GLOBENEWSWIRE
Agile Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Agile Therapeutics to Report Third Quarter 2023 Financial Results
26 Oct 2023 //
GLOBENEWSWIRE
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer
04 Oct 2023 //
GLOBENEWSWIRE
Agile to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
Agile Says It`s On Track To Hit $25-$30 Million In Its Second Quarter
17 Aug 2023 //
ACCESSWIRE
Agile Therapeutics Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Agile Therapeutics to Report Second Quarter 2023 Financial Results
26 Jul 2023 //
GLOBENEWSWIRE
Agile Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch
18 Jul 2023 //
ACCESSWIRE
Agile Sees Renewed Hope For Even Broader Adoption Of Weekly Birth Control Patch
11 Jul 2023 //
ACCESSWIRE
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
26 Jun 2023 //
GLOBENEWSWIRE
Agile Commends the Biden Administrations Commitment to Strengthening Access
23 Jun 2023 //
GLOBENEWSWIRE
Agile Therapeutics Announces the Availability of Twirla® through FPA Women™s
15 Jun 2023 //
GLOBENEWSWIRE
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services
13 Jun 2023 //
GLOBENEWSWIRE
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
25 May 2023 //
GLOBENEWSWIRE
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
22 May 2023 //
GLOBENEWSWIRE
Agile Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Agile Therapeutics to Report 1Q 2023 FYR and Provide Business Update
08 May 2023 //
GLOBENEWSWIRE
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
26 Apr 2023 //
GLOBENEWSWIRE
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
10 Apr 2023 //
GLOBENEWSWIRE
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results
22 Mar 2023 //
GLOBENEWSWIRE
Agile to Report Fourth Quarter and Full Year 2022 Financial Results
21 Mar 2023 //
GLOBENEWSWIRE
Agile Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement
27 Feb 2023 //
GLOBENEWSWIRE
Agile Provides Clinical Update on Twirla and Status of Pipeline Evaluation
01 Feb 2023 //
GLOBENEWSWIRE
Agile Therapeutics Announces Distribution of Series C Preferred Stock
26 Jan 2023 //
GLOBENEWSWIRE
Agile Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan
09 Jan 2023 //
GLOBENEWSWIRE
Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth
01 Dec 2022 //
GLOBENEWSWIRE
Agile Therapeutics to Report Third Quarter 2022 Financial Results
26 Oct 2022 //
GLOBENEWSWIRE
Agile Therapeutics Announces Reorganization of Leadership Team
07 Oct 2022 //
GLOBENEWSWIRE
Agile Therapeutics Reports Q2 2022 Rusult and Provides Corporate Update
11 Aug 2022 //
GLOBENEWSWIRE
Agile Therapeutics to Report Second Quarter 2022 Financial Results
28 Jul 2022 //
GLOBENEWSWIRE
Agile Therapeutics Updates Second Quarter 2022 Guidance
12 Jul 2022 //
GLOBENEWSWIRE
Agile Therapeutics to Participate in Maxim Group`s Upcoming Women`s Health Panel
08 Jul 2022 //
GLOBENEWSWIRE
Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering
06 Jul 2022 //
GLOBENEWSWIRE
Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering
01 Jul 2022 //
GLOBENEWSWIRE
Agile Therapeutics to Present at H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
Agile Tx Announces Findings of First-Year Post-Marketing PV in ACOG Poster
05 May 2022 //
GLOBENEWSWIRE
Agile Therapeutics to Report First Quarter 2022 Financial Results
03 May 2022 //
GLOBENEWSWIRE
Agile Therapeutics Announces 1-For-40 Reverse Stock Split
26 Apr 2022 //
GLOBENEWSWIRE
Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla
14 Apr 2022 //
GLOBENEWSWIRE
Agile Tx Receives $4.7M After Selling Net Operating Loss Tax Benefits
11 Apr 2022 //
GLOBENEWSWIRE
Agile Tx Announces Poster Presentation at the 2022 ACOG
07 Apr 2022 //
GLOBENEWSWIRE
Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z
31 Mar 2022 //
GLOBENEWSWIRE
Agile Therapeutics Reports Fourth Quarter & Full Year 2021 Financial Results
30 Mar 2022 //
GLOBENEWSWIRE
Agile Therapeutics Announces Closing of $4.85 Million Registered Direct Offering
14 Mar 2022 //
GLOBENEWSWIRE
Agile Therapeutics to Participate in Upcoming March Investor Events
11 Mar 2022 //
GLOBENEWSWIRE
Agile Tx to Host Q4 and FY 2021 Financial Results
07 Mar 2022 //
GLOBENEWSWIRE
Agile Tx, Afaxys Partner to Expand Access to Twirla Transdermal System
10 Jan 2022 //
GLOBENEWSWIRE
Aadi Bioscience Announces Publication of its Ph2 Registrational (AMPECT)
22 Oct 2021 //
GLOBENEWSWIRE
